These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 15795949)
1. Drug interaction between sevelamer and cyclosporin. Wauters JP; Uehlinger D; Marti HP Nephrol Dial Transplant; 2005 Mar; 20(3):660-1; author reply 661. PubMed ID: 15795949 [No Abstract] [Full Text] [Related]
2. Drug interaction between sevelamer and cyclosporin. Wauters JP; Uehlinger D; Marti HP Nephrol Dial Transplant; 2004 Jul; 19(7):1939-40. PubMed ID: 15199213 [No Abstract] [Full Text] [Related]
3. Sevelamer and pharmacokinetics of cyclosporin A after kidney transplantation. Uehlinger D; Marti HP; Jadoul M; Wauters JP Nephrol Dial Transplant; 2005 Mar; 20(3):661. PubMed ID: 15735254 [No Abstract] [Full Text] [Related]
4. Drug interaction between sevelamer and cyclosporin. Guillen-Anaya MA; Jadoul M Nephrol Dial Transplant; 2004 Feb; 19(2):515. PubMed ID: 14736993 [No Abstract] [Full Text] [Related]
5. Management of hyperphosphataemia in chronic renal disease: lessons from the past and future directions. Amato M; Aterini S Nephrol Dial Transplant; 2003 Apr; 18(4):848; author reply 848-9. PubMed ID: 12637666 [No Abstract] [Full Text] [Related]
6. Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. Burke S; Amin N; Incerti C; Plone M; Watson N J Clin Pharmacol; 2001 Feb; 41(2):193-8. PubMed ID: 11210401 [TBL] [Abstract][Full Text] [Related]
7. Oral calcium, sevelamer and vascular calcification in uraemic patients. Fournier A; Presne C; Oprisiu R; Sadek T Nephrol Dial Transplant; 2002 Dec; 17(12):2276-7. PubMed ID: 12454254 [No Abstract] [Full Text] [Related]
8. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Pieper AK; Buhle F; Bauer S; Mai I; Budde K; Haffner D; Neumayer HH; Querfeld U Nephrol Dial Transplant; 2004 Oct; 19(10):2630-3. PubMed ID: 15304561 [TBL] [Abstract][Full Text] [Related]
9. Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. Burke SK; Amin NS; Incerti C; Plone MA; Lee JW J Clin Pharmacol; 2001 Feb; 41(2):199-205. PubMed ID: 11210402 [TBL] [Abstract][Full Text] [Related]
10. Effect of phosphate binders on supplemental iron absorption in healthy subjects. Pruchnicki MC; Coyle JD; Hoshaw-Woodard S; Bay WH J Clin Pharmacol; 2002 Oct; 42(10):1171-6. PubMed ID: 12362933 [TBL] [Abstract][Full Text] [Related]
11. Dietary phosphorus reduction by pretreatment of human breast milk with sevelamer. Ferrara E; Lemire J; Reznik VM; Grimm PC Pediatr Nephrol; 2004 Jul; 19(7):775-9. PubMed ID: 15103549 [TBL] [Abstract][Full Text] [Related]
12. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283 [TBL] [Abstract][Full Text] [Related]
13. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Chertow GM; Raggi P; McCarthy JT; Schulman G; Silberzweig J; Kuhlik A; Goodman WG; Boulay A; Burke SK; Toto RD Am J Nephrol; 2003; 23(5):307-14. PubMed ID: 12915774 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212 [TBL] [Abstract][Full Text] [Related]